Low Grade Serous Ovarian Cancer clinical trials

Explore recruiting low grade serous ovarian cancer clinical trials.

Recruiting low grade serous ovarian cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Low Grade Serous Ovarian Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Phase II investigational study of pembrolizumab combination with chemotherapy in platinum-sensitive recurrent low-grade serous ovarian cancer

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Open-Label Extension Study to Provide Continued Access to Avutometinib Alone or in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP301)

Spain, France, Italy, Germany, Belgium, Ireland +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2 Study of Avutometinib (VS-6766, a Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 201)

Belgium, Spain, France, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

ALEPRO: abemaciclib and letrozole in estrogen receptor positive rare ovarian cancer

Belgium, France, Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Low Grade Serous Ovarian Cancer trials by city

Low Grade Serous Ovarian Cancer in Toronto Low Grade Serous Ovarian Cancer in Vancouver Low Grade Serous Ovarian Cancer in Montreal Low Grade Serous Ovarian Cancer in Calgary Low Grade Serous Ovarian Cancer in Edmonton Low Grade Serous Ovarian Cancer in Ottawa Low Grade Serous Ovarian Cancer in Winnipeg Low Grade Serous Ovarian Cancer in Quebec City Low Grade Serous Ovarian Cancer in Hamilton Low Grade Serous Ovarian Cancer in Kitchener Low Grade Serous Ovarian Cancer in London Low Grade Serous Ovarian Cancer in Halifax Low Grade Serous Ovarian Cancer in New York Low Grade Serous Ovarian Cancer in Los Angeles Low Grade Serous Ovarian Cancer in Chicago Low Grade Serous Ovarian Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease